| scholarly article | Q13442814 |
| P50 | author | Thomas F Patterson | Q56859142 |
| Nita L Seibel | Q89543834 | ||
| Kieren A Marr | Q90630865 | ||
| David W. Denning | Q30533462 | ||
| P2093 | author name string | Patricia M Flynn | |
| Voravit Ratanatharathorn | |||
| Andrew J Ullmann | |||
| Donald N Buell | |||
| Cornelia Becker | |||
| David P Facklam | |||
| Jo-Anne H van Burik | |||
| Wendi M Lau | |||
| P2860 | cites work | A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients | Q45097002 |
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 | ||
| A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. | Q46414215 | ||
| International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. | Q46784358 | ||
| Infliximab for steroid‐refractory acute GVHD: A case series | Q47606634 | ||
| A 7-year study of severe hospital-acquired pneumonia requiring ICU admission | Q47619717 | ||
| Death of a SARS case from secondary aspergillus infection | Q47928637 | ||
| Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area | Q56941303 | ||
| Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management | Q73118821 | ||
| Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning | Q73256320 | ||
| Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia | Q73336907 | ||
| Combination antifungal therapy | Q76381447 | ||
| Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital | Q77627982 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients | Q80405699 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis | Q28343919 | ||
| Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis | Q28343922 | ||
| Echinocandin antifungal drugs | Q29398696 | ||
| Aspergillosis case-fatality rate: systematic review of the literature | Q31918085 | ||
| Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant | Q33722115 | ||
| A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan | Q33980368 | ||
| Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent | Q33980499 | ||
| Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus | Q33983499 | ||
| Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group | Q34002098 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach | Q34791918 | ||
| Aspergillosis. Pathogenesis, clinical manifestations, and therapy | Q35038459 | ||
| Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. | Q35219729 | ||
| Micafungin: a therapeutic review | Q35917404 | ||
| Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. | Q38016840 | ||
| Therapeutic outcome in invasive aspergillosis | Q38970340 | ||
| Invasive Aspergillosis in Italian AIDS patients | Q40569326 | ||
| A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients | Q40577742 | ||
| Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study | Q40627960 | ||
| NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 | ||
| Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response | Q43699809 | ||
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | Q43864353 | ||
| The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants | Q44282950 | ||
| Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. | Q44360471 | ||
| Disseminated aspergillosis in intensive care unit patients: an autopsy study | Q44392075 | ||
| Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 | ||
| Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants | Q44482347 | ||
| Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 | ||
| Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin | Q44583938 | ||
| Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus | Q44819548 | ||
| Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis | Q45063490 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P6104 | maintained by WikiProject | WikiProject Medicine | Q4099686 |
| P1104 | number of pages | 13 | |
| P304 | page(s) | 337-349 | |
| P577 | publication date | 2006-05-06 | |
| P1433 | published in | Journal of Infection | Q6295344 |
| P1476 | title | Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. | |
| P478 | volume | 53 |
| Q37653647 | A clinical review of echinocandins in pediatric patients |
| Q36895839 | A comparative evaluation of properties and clinical efficacy of the echinocandins |
| Q36290698 | A review of clinical experience with newer antifungals in children |
| Q33816237 | Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases |
| Q36948094 | Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective |
| Q38101520 | Antifungal agents in current pediatric practice. |
| Q34400255 | Antifungal clinical trials and guidelines: what we know and do not know |
| Q38232492 | Antifungal combination therapy for invasive aspergillosis |
| Q37816399 | Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q38015090 | Antifungal therapy in children: an update |
| Q37873552 | Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy |
| Q43287630 | Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections |
| Q37159584 | Caspofungin for treatment of invasive aspergillus infections. |
| Q37081683 | Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients |
| Q40360694 | Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. |
| Q57518516 | Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions |
| Q38102782 | Combination antifungal therapy for invasive fungal infections in children and adults |
| Q30873926 | Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data |
| Q37000091 | Combination antifungal therapy for the treatment of invasive yeast and mold infections |
| Q36895652 | Combination antifungal therapy: the new frontier |
| Q36847555 | Combination antifungal therapy: what can and should we expect? |
| Q36960092 | Combination antifungals: an update |
| Q46933663 | Combination therapy for invasive aspergillosis |
| Q36422666 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia |
| Q28273738 | Comparison of echinocandin antifungals |
| Q37079099 | Current and future therapeutic options in the management of invasive aspergillosis |
| Q37885746 | Current evidence of antifungal prophylaxis and therapy in pediatric patients |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q53217028 | Current role of echinocandins in the management of invasive aspergillosis. |
| Q37463228 | Diagnosis and treatment of aspergillosis in children |
| Q46836740 | Early clinical experience with anidulafungin at a large tertiary care medical center |
| Q37822777 | Echinocandin antifungal drugs in fungal infections: a comparison |
| Q37718385 | Echinocandin pharmacodynamics: review and clinical implications. |
| Q92354498 | Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside |
| Q37892184 | Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections |
| Q34019188 | Echinocandins: the newest class of antifungals |
| Q37944001 | Efficacy and safety of current drug therapies for invasive aspergillosis |
| Q43811410 | Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT. |
| Q49557143 | Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study. |
| Q43468516 | Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders |
| Q51166051 | Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection. |
| Q39565084 | Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis |
| Q35923943 | Endogenous aspergillus endophthalmitis after kidney transplantation |
| Q35089772 | Epidemiology and treatment approaches in management of invasive fungal infections |
| Q37900678 | Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. |
| Q62241543 | Fungal infection in solid organ recipients |
| Q33896940 | Fungal infections in transplant and oncology patients |
| Q44790540 | Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi |
| Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
| Q37263430 | Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates |
| Q51037587 | In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. |
| Q42576501 | In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method |
| Q43680541 | Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry? |
| Q37213029 | Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine |
| Q58775551 | Invasive Aspergillosis in Children: Update on Current Guidelines |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q37916824 | Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients |
| Q42102339 | JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committ |
| Q35116492 | Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction |
| Q40270696 | Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. |
| Q34775518 | Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study |
| Q34337608 | Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials |
| Q35026516 | Micafungin in the treatment of invasive candidiasis and invasive aspergillosis |
| Q33397111 | Micafungin use in children |
| Q37535957 | Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients |
| Q27014780 | Micafungin: an evidence-based review of its place in therapy |
| Q42146568 | Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm |
| Q48194055 | Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature |
| Q35756513 | Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination |
| Q37405284 | Paradoxical echinocandin activity: a limited in vitro phenomenon? |
| Q49612998 | Pediatric Invasive Aspergillosis |
| Q33451082 | Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate |
| Q57746174 | Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins |
| Q35105985 | Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents |
| Q42285675 | Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q41688288 | Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment |
| Q35959480 | Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature |
| Q35889014 | Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications |
| Q28077381 | Recent developments in the management of invasive fungal infections in patients with oncohematological diseases |
| Q34190284 | Regulatory circuitry governing fungal development, drug resistance, and disease. |
| Q37669740 | Review of the pharmacology and clinical studies of micafungin |
| Q34543970 | Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis |
| Q37327086 | Sequential prescription of antifungals in invasive fungal infection: the importance of mechanism of action |
| Q37122826 | Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance |
| Q43115263 | Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug |
| Q36828156 | The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety |
| Q36742397 | The echinocandins |
| Q46600214 | The role of anidulafungin therapy in solid organ transplant recipients |
| Q38353420 | Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update |
| Q33613647 | Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin. |
| Q58765898 | Treatment of Aspergillosis |
| Q37469829 | Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
| Q37767359 | Use of Antifungal Combination Therapy: Agents, Order, and Timing |
| Q83392396 | [Antifungal therapy update: new drugs and medical uses] |
| Q51175114 | [Echinocandins in children]. |
| Q31129662 | [In vitro antifungal activity of voriconazole: New data after the first years of clinical experience]. |
| Q45942581 | [Potential of anidulafungin in combined therapy]. |
Search more.